[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-bifurcation-lesions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-bifurcation-lesions":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,72,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100590768","coronary-bifurcations-with-ischaemia-and-flow-assessment-100590768",false,"NCT06971718","Coronary Bifurcations With Ischaemia and Flow Assessment","Drug Coated Balloons in Coronary Bifurcation Lesions. A Feasibility Study Looking at Computational Flow Dynamics, Ischaemic and Anatomical Changes to the Bifurcation","Inclusion Criteria:\n\n* Age 18 or over\n* Any bifurcation lesion amenable to a provisional main vessel treatment strategy\n* A main vessel diameter of 2.5mm or more and side branch diameter of \\>2mm\n* Any patient with stable angina, silent ischaemia, unstable angina or NSTEMI\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Cardiogenic shock\n* LVEF \\\u003C30%\n* STEMI (as unable to give informed consent)\n* eGFR \\\u003C30\n* Severe asthma contraindicating use of adenosine\n* High degree AV block on 12 lead ECG precluding the use of adenosine\n* Pregnancy\n* Inability to consent\n* Left main stem coronary bifurcation lesions","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","OBSERVATIONAL","The coronary arteries are blood vessels that provide oxygen rich blood to the muscle of the heart. If these vessels become narrowed or blocked, this can lead to chest pain (called angina) or heart attacks. Narrowings are usually treated using metal scaffolds called drug eluting stents. However, in one in five cases where the narrowing occurs at a branching point, treating it with stents is more challenging and can cause complications. A possible alternative treatment is using a special type of balloon called a drug-coated balloon. This balloon is inflated in the blood vessel and releases medicine to help widen the blood vessel and the procedure is completed without leaving any metallic scaffold behind.\n\nThis study aims to compare drug coated balloons with drug eluting stents to see which treatment works better for narrowing that occurs at branching points. We will used advanced imaging techniques to create computer models of blood flow in the vessels, and we will follow up with patients over tie to see how well the treatments work.",[24],"Coronary Bifurcation Lesions",[26,27,28],"Drug coated balloons","Coronary bifurcation lesions","Computational flow dynamics","RECRUITING","2025-05-06",{"date":32,"type":33},"2025-05-14","ACTUAL",{"date":35,"type":33},"2023-10-10",{"date":37,"type":20},"2026-06-01",{"name":39,"class":40},"University of East Anglia","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100583795","mini-crush-or-controlled-balloon-crush-for-true-coronary-bifurcation-lesions-100583795","NCT06880978","Mini-Crush Or Controlled Balloon-Crush For True Coronary Bifurcation Lesions","Inclusion Criteria:\n\n* Aged \\>18\n* PCI with mini-crush or controlled balloon-crush\n* Complex coronary bifurcation lesion (Medina 0.1.1 and Medina 1.1.1)\n\nExclusion Criteria:\n\n* Non-complex bifurcation anatomy\n* Bail-out 2-stent (reverse mini-crush or reverse controlled balloon-crush)\n* ST-elevation myocardial infarction\n* Cardiogenic shock status\n* In-stent restenosis\n* A history of coronary artery bypass grafting\n* Implantation of bare-metal stent\n* End-stage hepatic or renal disease\n* \\\u003C1-year life expectancy",{"count":49,"type":20},400,"12 Months","The mini-crush technique is one of the leading 2-stent techniques frequently applied by interventional cardiologists to treat complex bifurcation lesions. In the last 20 years, many technical innovations and iterations of mini-crush technique have been developed, and it maintains its popularity among invasive cardiologists. Moreover, mini-crush and double kissing-crush techniques have been compared in terms of clinical results in both left main and non-left main coronary bifurcation patient populations and no significant difference was found. However, the most important challenges of the mini-crush technique are the rewiring and advancement of a 1:1 non-compliant side-branch balloon after the main branch stent has been implanted. These challenges usually necessitate the use of a low profile balloon or additional support maneuvers (such as anchor balloon). Recently, a novel modified mini-crush-crush technique (controlled balloon-crush) has been introduced to the literature and is one of the most up-to-date crush techniques. The main advantage of this technique over the contemporary mini-crush technique is that the side branch can be easily rewired and the 1:1 size non-compliant balloon can easily pass through the crushed stent structure in the ostial part of the side branch. The basic rationale of this is that the crushing of the side branch stent is done in a more controlled manner (by slowly deflation of the side branch stent balloon) and this causes less disruption of the stent cells. This prospective observational study aims to assess the procedural and 1-year clinical outcomes of the contemporary mini-crush and controlled balloon-crush (modified mini-crush) double stenting techniques in patients with true coronary bifurcation lesions.",[24,53,54,55,56],"Death","Myocardial Infarction (MI)","Stent Thrombosis","Stroke",[58,59,60,61],"Coronary bifurcation","death","revascularization","stenting","2025-03-17",{"date":64,"type":33},"2025-03-18",{"date":66,"type":33},"2025-03-03",{"date":68,"type":20},"2026-08-01",{"name":70,"class":71},"Istanbul Mehmet Akif Ersoy Educational and Training Hospital","OTHER_GOV",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":41},"100447019","progress-bifurcation-global-registry-100447019","NCT05100992","Progress Bifurcation Global Registry","Prospective Global Registry of Percutaneous Coronary Intervention in Bifurcation Lesions (PROGRESS-BIFURCATION)","Inclusion Criteria:\n\n* Over 18 years of age\n* undergoing bifurcation percutaneous coronary intervention",{"count":80,"type":20},4000,"Coronary bifurcation lesions are lesions (or blockages) that occur at or near the intersection of a major coronary artery and one of the arteries' side branches.\n\nNumerous techniques and devices have been developed to treat coronary bifurcations; however, these types of lesions remain some of the most challenging, both in terms of procedural success and outcome. This study is designed as an observational, multi-center registry that will collect information on treatment strategies and outcomes of consecutive patients undergoing percutaneous coronary interventions (PCI) in coronary bifurcations among various participating centers, in order to determine the frequency of bifurcation PCI, the procedural strategies utilized, and the procedural outcomes.",[83,24],"Coronary Artery Disease",[85,86],"bifurcation lesions","percutaneous coronary intervention","2021-10-20",{"date":89,"type":33},"2021-10-29",{"date":91,"type":33},"2020-04-23",{"date":93,"type":20},"2030-01",{"name":95,"class":40},"Minneapolis Heart Institute Foundation",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":41},"100431291","sirolimus-deb-in-coronary-bifurcation-lesions-100431291","NCT04896177","Sirolimus DEB in Coronary Bifurcation Lesions","A Prospective, Multicenter, Randomized Controlled, Non-inferior Clinical Trial to Evaluate the Efficacy and Safety of Sirolimus Drug-eluting Coronary Balloon Catheter in Treatment of Coronary Bifurcation Lesions","Inclusion Criteria:\n\n1. Male or Female that ages 18-85 year old;\n2. Having evidence of myocardial ischemia;\n3. Voluntarily participates in this study and signs the informed consent form (ICF);\n4. Sufficiently compliant with the study protocol and agreed to receive follow-up at 1 month ±7 days, 6 months ±14 days, 9 months ±30 days, 12 months ±30 days, and 24 months ±30 days, of which angiography was required at 9 months ±30 days;\n5. Angiography confirmed as de novo bifurcation lesion with side-branch stenosis (diameter) ≥70%;\n6. Suitable for PCI and side-branch lesions are not expected to stent implantation, and no drug-eluting balloon used for the main-branch. If a stent is implanted into the main-branch, it's usually necessary to perform a final balloon kissing on the two branches;\n7. Residual stenosis of the side-branch lesion ≦50% after pre-treatment, with a TIMI flow grade 3;\n8. The target vessel diameter was 2.0mm-4.0mm.\n\nExclusion Criteria:\n\n1. Women who is pregnant or lactating, or having a fertility plan within 1 year or are unwilling to take effective contraceptive measures;\n2. Cardiogenic shock patients;\n3. With hemorrhagic symptoms or active gastrointestinal ulcers, or previous stroke within 6 months, or who are expected to be unable to tolerate double-antibody therapy after interventional therapy;\n4. ST-segment elevation myocardial infarction (STEMI) occurred within one week before enrollment;\n5. With severe congestive heart failure or NYHA class Ⅳ heart failure;\n6. With severe valvuar heart disease;\n7. Heart transplant patients;\n8. With renal insufficiency (creatinine \\> 3.0mg\u002F dL or 265.2 umol \u002FL) and\u002For advanced renal disease requiring dialysis;\n9. With a life expectancy less than 1 year;\n10. With contraindications who cannot take aspirin and\u002For clopidogrel and\u002For ticagrelor;\n11. With known allergies to paclitaxel, sirolimus, contrast agents, etc.;\n12. Participating in clinical trials of other drugs or devices and has not met the primary endpoint;\n13. Non-target lesions cannot be processed before the target lesions or non-target lesions treatment fails;\n14. Intra-stent restenosis;\n15. High-risk left main disease;\n16. Other patients considered by the investigator to be unsuitable for inclusion.","85 Years",{"count":105,"type":20},280,"INTERVENTIONAL",[108],"NA","The purpose of this study is to evaluate the efficacy and safety of sirolimus drug-eluting coronary balloon catheter in treatment of coronary bifurcation lesions.\n\nThis is a prospective, multicenter, randomized controlled, non-inferior clinical trial, which would enroll 280 participants in total. Paticipants would undergoing PCI with sirolimus DEB or paclitaxel DEB, and be followed-up to 24 months.",[24],[112,113,114,115],"drug-eluting balloon","coronary bifurcation lesions","coronary heart disease","sirolimus","2021-05-20",{"date":118,"type":33},"2021-05-21",{"date":120,"type":33},"2021-03-18",{"date":122,"type":20},"2026-09-18",{"name":124,"class":125},"Shenzhen Salubris Pharmaceuticals Co., Ltd.","INDUSTRY"]